Virologist, full interview

Rant warning. There is a significant rant in this video starting at 15 minutes 20 seconds. Viewer discretion is advised as some may find this objectionable.Uploaded 22-07-22CDC variant nowcasthttps://covid.cdc.gov/covid-data-tracker/#variant-proportionsBA.5 77.9%BA.4 12.8%BA.2.12.1 8.6%BA.2 0.6%BA.1 0%Delta 0%Others 0%https://www.nytimes.com/interactive/2021/us/covid-cases.html?campaign_id=185&emc=edit_yct_20220722&instance_id=67312&nl=coronavirus-tracker®i_id=110300449&segment_id=99240&te=1&user_id=0b87b8c1eea981ec0514047bbfa553caRisk of death in vaccinated and unvaccinatedHospital admission risk goes up with ageMr. Biden, (79) isolating at homeFully vaccinated, had second booster, end of MarchTested positive, Thursday. very mild symptomsTaking PaxlovidWhite House has stringent measures to prevent infectionhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights5.77% in England (1 in 17 people)6.03% in Wales (1 in 17 people)4.82% in Northern Ireland (1 in 20 people) 6.48% in Scotland (1 in 15 people)Long covid, data to 27 May 2022 Coronavirus Infection Survey, 12 to 16 weeks laboratory-confirmed infectionBA.1 4.5% BA.2 4.2%Delta 5.0% of triple-vaccinated adults,Zoe datahttps://health-study.joinzoe.com/dataJapan, highest level of vigilance https://www.theguardian.com/world/2022/jul/22/japan-urges-highest-level-of-vigilance-as-omicron-subvariant-drives-record-covid-surgeNew wave of infectionsOmicron BA.5 subvariantCases, + 186,000, disproportionately affected children and young peopleRecent rise in cases, 60 +Lowest per capita rate of 38 OECD countries246 per million people Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Open access using this link:Uploaded 13-12-23https://onlinelibrary.wiley.com/doi/10.1111/eci.14136Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from AustriaEvidence is limited on the effectiveness of a fourth vaccine dose against coronavirus disease 2019,in populations with prior SARS-CoV-2 infections. We estimated the risk of COVID-19 deaths (primary outcome)We estimated the risk of SARS-CoV-2 infections (secondary outcome)MethodsAustria nationwide retrospective observational study. 1 November to 31 December 2022Primarily comparing individuals with four versus three vaccine doses. Whole population data.Results3,986,312 previously infected individuals281,291 (7,1%) had four vaccinations at baseline1,545,242 (38.8%) had three vaccinations at baseline We recorded69 COVID-19 deaths89,056 SARS-CoV-2 infectionsThe majority of COVID-19 deaths and a significant proportion of all-cause deaths occurred in nursing home residentsRelative vaccine effectiveness (rVE) for four versus three vaccine doses-24% against COVID-19 deaths17% against SARS-CoV-2 infections. Protection against infection rapidly diminished over time,and infection risk with four vaccinations was higher during extended follow-up until June 2023. Adjusted HR for all-cause mortality for four versus three vaccinations was 0.79.That is people with a 4th dose were only 79% as likely to die(Suggesting healthy vaccinee bias, i.e. healthier persons received more vaccine doses)DiscussionIn previously infected individuals, a fourth vaccination did not reduce COVID-19 death risk, but with transiently reduced risk of SARS-CoV-2 infections,and reversal of this effect in longer follow-up. All-cause mortality data suggest healthy vaccinee bias.More detailsMostly Pfizer vaccine, some ModernaIn this study, overall case fatality rate, 0.08%.(IFR, ? 0.008% if 10% of infections picked up)Individuals with repeated previous infections had reduced re-infection riskNatural immunity may be a main determinant of immunological protection in a populationBy end 2022, the vast majority of the global population had already acquired some immune protectionCompared to three vaccine doses, those with fewer or no vaccinations did not differ with regard to COVID-19 mortality,but had reduced risk of SARS-CoV-2 infections.In 2022, infection fatality rates due to SARS-CoV-2 significantly declined suggesting transitioning into endemicity.In general, our study results question whether recommendations for repeated vaccine boosters against SARS-CoV-2 are currently justified for large parts of the general population with a history of previous infections. Measures against SARS-CoV-2 including vaccine policy should be critically re-assessed for their risk-to-benefit ratio.As most SARS-CoV-2 infections are asymptomatic or mild in an endemic phase, effectiveness of vaccinations should be primarily evaluated according to hard clinical outcomes (e.g. COVID-19 deaths)Extended follow-upFrom 1 January to 30 June 2023Omicron XBB.1.5. was the predominant variant225 COVID-19 deaths174,174 SARS-CoV-2 infections. Analyses in 2023 confirm no relative vaccine effectiveness (rVE) for four versus three vaccine doses for COVID-19 mortality,but show higher risk of SARS-CoV-2 infections with a rVE of −17%Free download John’s textbooks in high res pdf.https://drjohncampbell.co.ukCheck out Campbell's Physiology Notes Dr John Campbell Sold by author on eBay!https://www.ebay.co.uk/itm/155780745424?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=K6raxMZrQnm&sssrc=4429486&ssuid=K6raxMZrQnm&var=&widget_ver=artemis&media=EMAIL Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Virus being experimented on in China. https://www.researchgate.net/publication/377199018_Lethal_Infection_of_Human_ACE2-Transgenic_Mice_Caused_by_SARS-CoV-2-related_Pangolin_Coronavirus_GX_P2Vshort_3UTR

Download a free copy of VITAMIN D3 and the Great Biology Reset, by Professor David Anderson and Dr David Grimes. https://dgreatbiologyreset.com/#download

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)